secwatch.observer — SEC 8-K summary
======================================

Issuer:     CDT Equity Inc. (CDT)
CIK:        0001896212
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0001493152-24-030681
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Conduit licenses three AstraZeneca assets for autoimmune and infertility; issues 9.5M shares
--------------------------------------------------------------------------------

- Exclusive license from AstraZeneca for HK-4 glucokinase activators AZD1656, AZD5658 and MPO inhibitor AZD5904.
- Conduit pays $1.5M upfront and issues 9.5M shares to AstraZeneca; AstraZeneca gets sublicense revenue share.
- AstraZeneca receives right of first negotiation if Conduit seeks third-party rights to licensed compounds.
- Conduit plans to initiate Phase II trials in autoimmune disorders and idiopathic male infertility in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1896212/000149315224030681/0001493152-24-030681-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1896212/000149315224030681/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-030681

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer